In phase 2 study of INO-5401 in combination with cemiplimab, Inovio Pharmaceuticals Inc (NASDAQ:INO) achieved success in ensuring the progression-free survival of patients who are diagnosed with GBM (glioblastoma multiforme). The phase 2 study is conducted using INO 9012, and INO 5401 in combination with a PD-1 blocking antibody – Libtayo on fifty-two patients diagnosed […]
Inovio Pharmaceuticals Inc (NASDAQ:INO)
Recent Posts
Colombia Oil and Gas 2023 Congress – Status and Developments Prospects of Oil and Gas industry in Latin America
Mike The Pike Productions, Inc. (OTC: MIKP) Announces Virtual Shareholder Conference July 25, 2023
Künstliche Intelligenz im Kinderherz-Zentrum
Auri Inc. – Dividend, Retirement Timelines and Expectations
Auto Parts 4Less Group, Inc. Unveils Significant Business Progress and Future Plans in Latest Investor Update
Popular Post
-
Japanese Premier Declares COVID-19 State of Emergency in Tokyo
-
Expect Even More Unique Electric Cars Says Ferrari
-
4CABLE TV INTERNATIONAL, INC. ANNOUNCES SETTLEMENT OF THE MARQUIS TRADING DEBT, OPENING OF THE FIRST OF ITS KIND HIP RESTAURANT AND THE UNDERGOING OF REPAIRS AT THE CIGN FARM
-
BT and Ericsson Partners to Build Private 5G Networks
-
U.S Resumes Talks With Embattled Huawei CFO Meng Wanzhou
